Cipamfylline
Alternative Names: BRL 61063; HEP 688Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Class Antiallergics; Antiasthmatics; Antineoplastics; Antivirals; Xanthines
- Mechanism of Action Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atopic dermatitis; Viral infections
Most Recent Events
- 13 May 2003 Cipamfylline is no longer licensed to LEO Pharma
- 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Canada (Topical)
- 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Europe (Topical)